Synergistic Regulation of Tumor Immunity by Integrins and Lectins: From Molecular Mechanisms to Dual-Targeted Therapy
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188245 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Rongyang Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Guilin Medical University, Guilin 541199, China. Hauptthemen laut MEDLINE: Integrins, Neoplasms, Lectins. Die Arbeit nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangxi Natural Science Foundation Project, Guangxi Provincial College Students' innovation and entrepreneurship training program.
Abstract (Originalsprache)
The high invasiveness and metastatic potential of malignant tumors represent major obstacles to successful clinical treatment and are closely associated with poor patient prognosis. These processes rely heavily on the dynamic remodeling of the tumor microenvironment. Within this milieu, integrins—a family of transmembrane receptors mediating cell–matrix and cell–cell interactions—along with lectins capable of recognizing specific carbohydrate structures, form a complex and coordinated regulatory network that collectively drives tumor progression. This review systematically elucidates the key mechanisms by which this network regulates the malignant phenotype of tumor cells, mediates microenvironmental interactions, induces therapy resistance, and reshapes the immunosuppressive tumor microenvironment. Drug development strategies targeting this network have evolved from single-target inhibition toward intervention in coordinated signaling pathways. However, clinical translation remains challenged by tumor heterogeneity, complex resistance mechanisms, and off-target toxicity. Therefore, future efforts aimed at deepening our understanding of their regulatory roles within the tumor immune microenvironment, along with optimizing immune-based combination therapies, will provide valuable insights for both basic research and clinical translation in this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Guilin Medical University, Guilin 541199, China.
- Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin 541199, China.
- College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Förderung
- National Natural Science Foundation of China
- Guangxi Natural Science Foundation Project
- Guangxi Provincial College Students' innovation and entrepreneurship training program
- Guangxi Provincial College Students’ innovation and entrepreneurship tIntegrins
Zitieren
APA
Liu, R., Liu, C., Guo, X., Li, P., Niu, Y., Zhao, J., Zhang, J., Su, X., Chen, J., Jin, J., & Yang, J. (2026). Synergistic Regulation of Tumor Immunity by Integrins and Lectins: From Molecular Mechanisms to Dual-Targeted Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188245
Vancouver
Liu R, Liu C, Guo X, Li P, Niu Y, Zhao J, et al. Synergistic Regulation of Tumor Immunity by Integrins and Lectins: From Molecular Mechanisms to Dual-Targeted Therapy. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188245
BibTeX
@article{Liu2026,
author = {Liu, Rongyang and Liu, Chen and Guo, Xiaotong and Li, Peiyan and Niu, Yewei and Zhao, Jiawei and Zhang, Jingyi and Su, Xiaolin and Chen, Jian and Jin, Jiamin and Yang, Jinfeng},
title = {Synergistic Regulation of Tumor Immunity by Integrins and Lectins: From Molecular Mechanisms to Dual-Targeted Therapy},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188245}
}
EUVIMED